Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10258877 | 0.88 | KMT2A (0.39) | HTR1AKMT2AMEN1HPGDPOLB | |
| SCHEMBL10288026 | 0.88 | HTR1A (0.39) | HTR1AKMT2AMEN1ADRA1ADRD2 | |
| SCHEMBL2920191 | 0.81 | HPGD (0.46) | KMT2AMEN1HPGDPOLBPKM | |
| SCHEMBL3438856 | 0.81 | KMT2A (0.50) | HTR1AKMT2AMEN1HPGDPOLB | |
| SCHEMBL2109099 | 0.79 | TP53 (0.49) | KMT2AMEN1HPGDPOLB | |
| SCHEMBL2110061 | 0.78 | HPGD (0.52) | HTR1AKMT2AHPGDPOLBADRA1A | |
| SCHEMBL3841546 | 0.66 | TACR1 (0.55) | HTR1AKMT2AHPGDPOLBPKM | |
| SCHEMBL4992623 | 0.64 | AVPR1A (0.57) | HTR1AKMT2AMEN1HPGDPOLB | |
| SCHEMBL2109322 | 0.64 | PRSS1 (0.61) | KMT2AMEN1 | |
| SCHEMBL15788702 | 0.62 | PRSS1 (0.40) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | TPSAB1, TPSB2, TPSD1 | HTR1A 53/4885KMT2A 3421/4885MEN1 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.